| Objective : This study focused on the patients with middle and advanced lung adenocarcinoma with negative driver gene of deficiency of qi and blood,and discussed the difference in the therapeutic effect and safety of modified bazhen decoction combined with chemotherapy compared with chemotherapy alone for patients with middle and advanced lung adenocarcinoma with negative driver gene of deficiency of qi and blood,so as to provide certain research basis for the combined treatment of traditional Chinese and western medicine for patients with middle and advanced lung adenocarcinoma with negative driver gene of deficiency of qi and blood.Methods:In this clinical study,a total of 60 patients with pathologically diagnosed advanced lung adenocarcinoma who were negative for gene test driver gene and TCM syndrome differentiation for the deficiency of qi and blood type were divided to treatment groups and control groups.The control group received chemotherapy with two drugs containing platinum for 2 cycles.In the treatment group,the control group was given treatment,and the oral treatment with modified bazhen decoction was combined for 2cycles during chemotherapy.The patients' chest CT was improved before and after treatment,and the distribution of T cell subgroups and CEA were detected.After 2cycles of treatment,the objective efficacy,TCM syndrome score,KPS score,T cell changes,tumor marker CEA and safety of the two groups of patients were compared,and the data were analyzed using statistical methods.Results:Baseline comparison: The two groups were compared in terms of gender,age,tumor stage,chemotherapy regimen,TCM syndrome score before treatment,KPS score,T cell subgroup distribution,CEA and other baseline data,with no statistically significant difference(P > 0.05).Objective curative effect of Tumor: The overall objective response rate of thetreatme nt group was 33.3% for DCR and 77.8% for ORR.The overall objective remission rate of the control group was 27.0% for DCR and 73.1% for ORR?Efficacy of clinical symptoms: the total effective rate of clinical symptoms was 65.4%in the control group and 88.9% in the treatment group,with statistically significant differences(P < 0.05).Quality of life: KPS scores of the control group and the treatment group after treatment were compared,and the difference was statistically significant(P < 0.05).The distribution of T cell subsets: After 2-cycles of treatment,there was obvious difference in CD4+T between the two group after treatment(P < 0.05),and no statistically significant difference in CD3+T,CD8+T,and CD4+/CD8+(P>0.05).The comparison between the two groups showed that there were statistically significant differences in CD4+T,CD8+T and CD4+/CD8+ after treatment(P < 0.05),and no statistically significant differences in CD3+T before treatment(P > 0.05).CEA: After 2-cycle treatment,there were significant differences in CEA between the treatment group and the control group(p<0.05),and between the Control Group and the treatment group(p < 0.05).Safety: There was no significant difference in overall safety between the treatment group and the control group(P > 0.05).There were statistically significant differences between the two groups in the incidence of fatigue,granulocytopenia,decreased hemoglobin,and liver and kidney function injury(P<0.05),and no statistically significant differences in the incidence of nausea,vomiting,and diarrhea(P > 0.05).Conclusion : For negative-drive gene middle-late stage lung adenocarcinoma patients of deficiency of qi and blood,chemotherapy combination with modified bazhen decoction comparing single chemotherapy although cann't improve the clinical curative effect,but can significantly enhance clinical symptom curative effect,life quality,improved obviously after chemotherapy in patients with CD4+ T and improve theability of immune activation,further reduce the serum levels of tumor markers,reduce fatigue during treatment,granulocytopenia and hemoglobin reduces and the damage o f liver and kidney function. |
PDF Full Text Request